KR19990078610A - Skin Care Composition For Improvement Of The Water-retaing Capacity Of The Skin And Restoration Of a Damaged Skin - Google Patents

Skin Care Composition For Improvement Of The Water-retaing Capacity Of The Skin And Restoration Of a Damaged Skin Download PDF

Info

Publication number
KR19990078610A
KR19990078610A KR1019990026753A KR19990026753A KR19990078610A KR 19990078610 A KR19990078610 A KR 19990078610A KR 1019990026753 A KR1019990026753 A KR 1019990026753A KR 19990026753 A KR19990026753 A KR 19990026753A KR 19990078610 A KR19990078610 A KR 19990078610A
Authority
KR
South Korea
Prior art keywords
skin
composition
cholesterol
present
ceramide
Prior art date
Application number
KR1019990026753A
Other languages
Korean (ko)
Inventor
김현준
Original Assignee
김현준
주식회사 인터코즘바이오텍
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 김현준, 주식회사 인터코즘바이오텍 filed Critical 김현준
Priority to KR1019990026753A priority Critical patent/KR19990078610A/en
Priority to CA002281430A priority patent/CA2281430A1/en
Priority to JP11250846A priority patent/JP2001039859A/en
Priority to FR9911061A priority patent/FR2794366A1/en
Priority to IT99MI001884 priority patent/IT1314186B1/en
Publication of KR19990078610A publication Critical patent/KR19990078610A/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00Cosmetics or similar toiletry preparations
    • A61K8/18Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/33Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
    • A61K8/36Carboxylic acids; Salts or anhydrides thereof
    • A61K8/361Carboxylic acids having more than seven carbon atoms in an unbroken chain; Salts or anhydrides thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/16Amides, e.g. hydroxamic acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/21Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/66Phosphorus compounds
    • A61K31/683Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
    • A61K31/685Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols one of the hydroxy compounds having nitrogen atoms, e.g. phosphatidylserine, lecithin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00Cosmetics or similar toiletry preparations
    • A61K8/18Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/33Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
    • A61K8/37Esters of carboxylic acids
    • A61K8/375Esters of carboxylic acids the alcohol moiety containing more than one hydroxy group
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00Cosmetics or similar toiletry preparations
    • A61K8/18Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/55Phosphorus compounds
    • A61K8/553Phospholipids, e.g. lecithin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00Cosmetics or similar toiletry preparations
    • A61K8/18Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/63Steroids; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00Cosmetics or similar toiletry preparations
    • A61K8/18Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/68Sphingolipids, e.g. ceramides, cerebrosides, gangliosides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/02Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/10Anti-acne agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61QSPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00Preparations for care of the skin

Abstract

본 발명은 세라마이드(Ceramide) 및 스핀고리피드(Sphingolipid)의 효능을 충분히 발휘하기 위해 피부세포막과 동일한 조성물 및 구조적 성질을 갖는 피부보호(Skin Care)용 조성물 및 그의 제조방법을 제공하는데 그 목적이 있다.An object of the present invention is to provide a composition for skin care having the same composition and structural properties as the skin cell membrane and a method for producing the same in order to fully exhibit the efficacy of ceramide and spinolipid. .

본 발명의 조성물은 각질층 세포간 주요성분인 세라마이드, 콜레스트롤, 지방산을 비롯하여 피부내피 세포막의 주성분인 레시틴, 트리글리세라이드 및 생리활성물질인 피토스핀고신 혹은 그 유도체로 구성되어 있다.The composition of the present invention is composed of the main components of the stratum corneum cells, ceramides, cholesterol, fatty acids, lecithin, triglycerides, and phytospinosine or its derivatives, which are the main components of the skin endothelial cell membrane.

본 발명에 의해 제조된 피부 보호용 조성물은 세라마이드가 피부세포막과 다른 조성물로 혼합된 제품에 비해 부작용이 없고 피부 침투성과 보습력이 월등히 뛰어난 결과를 보였다. 이는 본 발명의 조성물이 피부 각질층의 수분손실을 크게 감소시켜 피부장벽 기능을 향상시킴으로서 보습효과가 뛰어남을 입증하는 것이라 할 수 있다. 또한 다른 소수성(hydrophobic) 혹은 수용성의 치료활성 성분 (Therapeutic Active Ingrediens)과 상용성이 좋을 뿐만 아니라 약물 전달성이 뛰어나 여드름이나 피부상처 치유에도 효과가 큰 것으로 입증되었다.The skin protection composition prepared by the present invention has no side effects and excellent skin permeability and moisturizing ability compared to the product of ceramide mixed with the skin cell membrane and other compositions. This can be said that the composition of the present invention greatly reduces the water loss of the stratum corneum layer to improve the skin barrier function, excellent moisturizing effect. In addition, its compatibility with other hydrophobic or water-soluble therapeutic active ingredients (Therapeutic Active Ingrediens), as well as excellent drug delivery, has been proven to be effective in healing acne and skin wounds.

Description

피부 보호용 조성물 {Skin Care Composition For Improvement Of The Water-retaing Capacity Of The Skin And Restoration Of a Damaged Skin}Skin Care Composition For Improvement Of The Water-retaing Capacity Of The Skin And Restoration Of a Damaged Skin}

본 발명은 사람의 피부세포간(Intercellular)에 존재하는 생체막과 동일한 지질 조성물과 구조적 성질을 가진 피부 보호용 조성물에 관한 것이다.The present invention relates to a composition for protecting skin having the same lipid composition and structural properties as a biological membrane present in human intercellular skin (Intercellular).

건강한 피부상태를 유지하기 위한 가장 바람직한 피부 응용 제품을 개발하기 위해서는 피부의 구조와 피부세포의 생체막 조성물 및 물리적 성질을 충분히 이해 하는 것이 바람직하다.In order to develop the most desirable skin application products for maintaining a healthy skin condition, it is desirable to fully understand the structure of the skin and the biofilm composition and physical properties of skin cells.

피부의 구조는 기저층(Basal layer)으로부터 각화세포(Keratinocyte Cell)의 분화에 따라 내피(Dermis), 외피(Epidermis), 각질층(Stratum Corneum) 으로 분류된다.The structure of the skin is divided into dermis, epidermis and stratum corneum according to differentiation of keratinocyte cells from the basal layer.

피부세포간 조성물은 지질 이중층(Lipid Lamellar Bilayer) 구조로 되어 있고 피부층에 따라 지질 조성물이 변하고 있다.The intercellular skin composition has a lipid lamellar bilayer structure and the lipid composition is changing according to the skin layer.

특히 피부 최외각층인 각질층은 외부의 물리 화학적인 환경으로부터 일차적으로 피부를 보호하는 기능뿐만 아니라 내부의 수분 손실을 방지하는 중요한 피부장벽(Skin Barrier) 기능을 하고있다. 건조한 피부는 여러 가지 피부질환의 원인이 되므로 피부가 보습력을 유지하도록 하는 것이 피부 보호의 기본이다.In particular, the stratum corneum, which is the outermost layer of skin, not only protects the skin primarily from the external physicochemical environment but also plays an important skin barrier function to prevent internal moisture loss. Dry skin can cause a variety of skin diseases, so keeping the skin moisturizing is the basis of skin protection.

또한 피부는 수많은 외부의 미생물로부터 노출되어 있고 피부가 정상적인 상태(Normal Bacterial Flora)로 유지하기 위한 피부 조성물이 각질층에 있는 것으로 알려져 있다. [Tannock, G.W., in "Normal Microflora"(Eds. Chapman & Hall), pp 3~8, 1995].It is also known that the skin is exposed to numerous external microorganisms and there is a skin composition in the stratum corneum to keep the skin in a normal state (Normal Bacterial Flora). Tannock, G.W., in "Normal Microflora" (Eds. Chapman & Hall), pp 3-8, 1995.

따라서 각질층 세포간에 존재하는 지질 조성물과 이들의 물리화학적 성질과 생물학적 기능을 규명하는 연구가 지난 10년간 진행되어 왔다.Therefore, studies have been undertaken over the past decade to identify lipid compositions present between stratum corneum cells and their physicochemical properties and biological functions.

일반적으로 인지질(Phospholipids)은 세포간 조성물에 있어서 지질 이중층을 형성하는 중요한 성분이나 피부 외곽층으로 갈수록 세포막의 조성물에는 인지질의 함량이 줄어들고 세라마이드(Ceramide)의 함량이 증가되어 피부보호기능을 하는 각질층의 세포간 지질 조성물은 세라마이드가 40%, 콜레스트롤(Cholesterol)이25%, 지방산이 25%, 콜레스트롤술페이트(cholesterolsulfate)가 10%로 구성된다.In general, phospholipids (Phospholipids) is an important component that forms a lipid bilayer in the intercellular composition, but the composition of the cell membrane decreases the phospholipid content and increases the content of ceramide in the stratum corneum. The intercellular lipid composition is composed of 40% ceramide, 25% cholesterol, 25% fatty acid, and 10% cholesterol.

세라마이드는 각질층의 수분의 손실방지와 손상된 피부 보호층을 복원하는 중요한 성분으로 알려져 있다.Ceramide is known as an important ingredient that prevents the loss of moisture in the stratum corneum and restores damaged skin protection layers.

세라마이드의 전구체중 하나인 피토스핀고신(Phytosphingosine)은 각질층에 존재하는 함량은 적으나 미생물로부터 피부를 정상상태로 유지해 주는 항생제 역할을 하는 것으로 최근에 알려 지고 있다.(Bibel, D.J. et al.: "Topical sphingolipids in antisepsis and antifungal threapy:Clinical and Experimental Dermatology" 1995;20, pp 395-400. -Bibel, D.J. et al.:"Antimicrobial Activity of Stratum Corneum Lipids from Normal and Essential fatty Acid-Deficient Mice":J Invest Dermatol 92:632-638,1989. - Bibel, D.J. et al.: "Antimicrobial Activity of Sphingosines:J Invest Dermatol 98: 269-273, 1992)Phytosphingosine, one of the precursors of ceramide, has recently been known to act as an antibiotic that keeps the skin in a normal state from microorganisms even though it is present in the stratum corneum (Bibel, DJ et al .: " Topical sphingolipids in antisepsis and antifungal threapy: Clinical and Experimental Dermatology "1995; 20, pp 395-400. -Bibel, DJ et al.:"Antimicrobial Activity of Stratum Corneum Lipids from Normal and Essential fatty Acid-Deficient Mice": J Invest Dermatol 92: 632-638,1989.- Bibel, DJ et al .: "Antimicrobial Activity of Sphingosines: J Invest Dermatol 98: 269-273, 1992)

또한 아토피성 피부병(Atopic dermatitis)등 여러 피부질병이 각질층의 지질보호막을 구성하는 지질조성의 비정상적인 변화에 기인하는 것으로 알려지면서 세포막의 중요 성분인 세라마이드, 콜레스트롤, 지방산을 복합한 제품의 개발이 Dermatology분야와 화장품분야의 새로운 경향을 나타내고 있다.(Mao-Qiang M.Feingold KR. Thornfeldt CR, Elias PM:"Optimization of physilogical lipid mixtures for barrier repair. J Invest Dermatol 106:1096-1101, 1996)In addition, various skin diseases such as atopic dermatitis are known to be caused by abnormal changes in lipid composition constituting the lipid protective film of the stratum corneum, and development of products combining ceramides, cholesterol, and fatty acids, which are important components of cell membranes, has been developed in Dermatology field. (Mao-Qiang M.Feingold KR.Thornfeldt CR, Elias PM: "Optimization of physilogical lipid mixtures for barrier repair. J Invest Dermatol 106: 1096-1101, 1996).

이런 연유로 인해 각질층의 지질과 피토스핀고신을 이용한 피부 보호용 제품의개발에 많은 연구가 이루어지고 있다. 이들 물질이 충분히 생리적 활성을 나타내기 위해서는 각질층을 통과하여 인지질로 구성된 피부내피 세포막을 통과하여야 한다. 이를 위해서는 피부세포막과 유사한 구조를 갖는 지질층(Lipid Lamellar) 제품을 개발해야 한다.Due to these reasons, much research is being conducted on the development of skin protection products using lipids and phytospinosine in the stratum corneum. In order for these substances to exhibit sufficient physiological activity, they must pass through the stratum corneum and through the skin endothelial cell membrane consisting of phospholipids. To this end, it is necessary to develop a lipid layer (Lipid Lamellar) product having a structure similar to the skin cell membrane.

그러나 세라마이드 및 피토스핀고신의 소수성(Hydrophobic)으로 인하여 용해성(Solubility)이 낮고 결정화되기가 쉽기 때문에 사용량에 제한이 따르고, 프로필렌글리콜/에탄올과 같은 피부에 적합하지 않은 용제와 여러 가지 첨가제의 사용으로 인하여 부작용 및 피부 투과성에 문제점이 초래되었다.(-De Paepe K, Vandamme P, Roseeuw D, Rogiers V:Ceramides/Cholesterol/free fatty acids containing cosmetics: The effect on the barrier function. S?W-Journal 122:199-204, 1996. - de Groot AC, Weyland JW, Nater JP: Unwanted effects of cosmetics and drugs used in dermatology. In: de Groot AC, Weyland JW, Nater JP(eds.). Elsevier, Amsterdam, 1994, 3rd. ed, pp 770).However, due to the hydrophobicity of ceramide and phytospingosin, the solubility is low and it is easy to crystallize, so the amount of usage is limited, and due to the use of solvents and various additives that are not suitable for skin such as propylene glycol / ethanol Side effects and problems with skin permeability have resulted (-De Paepe K, Vandamme P, Roseeuw D, Rogiers V: Ceramides / Cholesterol / free fatty acids containing cosmetics: The effect on the barrier function.S? W-Journal 122: 199 -204, 1996.- de Groot AC, Weyland JW, Nater JP: Unwanted effects of cosmetics and drugs used in dermatology.In: de Groot AC, Weyland JW, Nater JP (eds.). Elsevier, Amsterdam, 1994, 3rd. ed, pp 770).

이런 문제점을 해결하기 위해 용해성 및 사용성이 뛰어난 세라마이드와 유사한 슈도세라마이드(Pseudo Ceramide)를 합성한 제품이 나오고 있지만 이들 제품은 피부에 쉽게 축적되고 생분해가 되지 않는다는 단점이 있었다.In order to solve this problem, products having synthesized pseudo ceramide (Pseudo Ceramide) similar to solubility and ease of use of ceramides have been produced, but these products have a disadvantage in that they are easily accumulated in the skin and are not biodegradable.

따라서 피부에 미치는 세라마이드 및 피토스핀고신의 효능을 충분히 발휘하기 위해서는 어떤 특별한 제제(Formulation)가 요구되어지며, 이런 문제점들을 해결하기 위한 방안으로써 본 발명자는 피부친화력이 우수한 즉, 피부세포막과 동일한 조성 과 구조적 성질을 가진 피부보호용 조성물을 개발하게 되었다.Therefore, in order to fully demonstrate the effects of ceramide and phytospinosine on the skin, a special formulation is required. As a solution to these problems, the present inventors have excellent skin affinity, that is, the same composition as that of the skin cell membrane. To develop a composition for protecting the skin having structural properties.

본 발명은 세라마이드(Ceramide) 및 스핀고리피드(Sphingolipid)의 효능을 충분히 발휘하기 위해 피부세포막과 동일한 조성물 및 구조적 성질을 갖는 피부보호(Skin Care)용 조성물 및 그의 제조방법을 제공하는데 그 목적이 있다.An object of the present invention is to provide a composition for skin care having the same composition and structural properties as the skin cell membrane and a method for producing the same in order to fully exhibit the efficacy of ceramide and spinolipid. .

본 발명의 조성물은 각질층 세포간 주요성분인 세라마이드, 콜레스트롤, 지방산을 비롯하여 피부내피 세포막의 주성분인 레시틴, 트리글리세라이드 및 생리활성물질인 피토스핀고신 혹은 그 유도체로 구성되어 있다.The composition of the present invention is composed of the main components of the stratum corneum cells, ceramides, cholesterol, fatty acids, lecithin, triglycerides, and phytospinosine or its derivatives, which are the main components of the skin endothelial cell membrane.

이와 같이 본 발명에서는 피부세포막에 존재하는 천연물질만을 이용하고 프로필렌글리콜/에탄올(Propylene glycol/ethanol)과 같은 용제나 합성계면 활성제를 사용하지 않음으로써 피부친화성이 높고 부작용이 없는 조성물을 개발할 수 있게 되었다.As such, in the present invention, by using only natural substances present in the skin cell membrane and not using a solvent such as propylene glycol / ethanol or a synthetic surfactant, it is possible to develop a composition having high skin affinity and no side effects. It became.

본 발명에 사용한 세라마이드는 스핀고신(Sphingosine), 스핀가닌(Sphinganine), 피토스핀고신(Phytosphingosine)의 유도체들로써 순수한 형태 및 2개 이상의 혼합물을 이용하였다. 세라마이드 1, 2, 3, 4, 5, 6I, 6II 의 군도 포함된다.Ceramide used in the present invention was used as a derivative of Spingosine (Sphingosine), Spinganine (Sphinganine), Phytosphingosine in pure form and a mixture of two or more. Groups of ceramides 1, 2, 3, 4, 5, 6I, 6II are also included.

(본 발명에서 사용한 세라마이드 유도체)(Ceramide derivative used in the present invention)

1. 스핀고신유도체1.Spin high reductant

2. 스핀가닌유도체2. Spinganine Derivatives

3. 피토스핀고신유도체3. Phytospinosine derivatives

R은 탄소수가 6∼25인 포화 및 불포화 지방산으로서 불포화 지방산인 경우에는 이중결합수가 1∼2개가 있으며, 포화지방산인 경우에는 α 또는 β위치에 수산기(Hydroxy group)를 갖고 있다.R is a saturated and unsaturated fatty acid having 6 to 25 carbon atoms. In the case of unsaturated fatty acids, R has 1 to 2 double bonds, and in the case of saturated fatty acids, R has a hydroxyl group at the α or β position.

본 발명에서 사용된 피토스핀고신은 그 자체로 사용하기도 하였으나 피토스핀고신의 유화력과 수용성을 높이기 위해 다음과 같은 극성을 띠는 유도체로 변형하여 사용할 수 있다.Although phytospinosine used in the present invention is used as such, it can be used by modifying the derivative having the following polarity to increase the emulsification power and water solubility of phytospinosine.

1. 유기염.Organic salt

유기산을 이용하여 pH가 중성인 유기염을 만들었으며 사용한 유기산은 염화수소, 젖산을 비롯한 α- 혹은 β-Hydroxy Acid, Salicylic Acid 등이다.Organic salts were used to make organic salts with neutral pH. The organic acids used were hydrogen chloride, lactic acid and other α- or β-hydroxy acid and salicylic acid.

2. 양이온2. cation

피토스핀고신의 아민(Amine)기에 메칠(Methyl)기를 도입하여 N,N,N-트리메칠피토스핀고신(N,N,N-Trimethyl phytosphingosine)을 합성하였다.N, N, N-trimethyl phytosphingosine was synthesized by introducing a methyl group to the amine group of phytospingosin.

3. Tetraacetylphytosphingosine(TAPS)Tetraacetylphytosphingosine (TAPS)

피토스핀고신으로부터 합성하여 사용하였다.It was synthesized from phytospinosine and used.

본 발명에 사용한 콜레스트롤과 그 유도체들은 피부세포막과 동일한 구조를 갖는 세라마이드의 액정(Liquid Lamellar Crystallization)형성에 도움을 주고 이 액정을 안정화시키는 물질로서 콜레스트롤, 콜레스트롤설페이트,콜레스트롤헤미숙시네이트(Cholesterol hemisuccinate)를 이용하였다.Cholesterol and its derivatives used in the present invention assist in the formation of liquid crystals (Liquid Lamellar Crystallization) of ceramides having the same structure as the skin cell membranes and stabilize the liquid crystals. Cholesterol, cholesterol, cholesterol hemisuccinate (Cholesterol hemisuccinate) Was used.

본 발명에 사용한 지방산은 탄소수 6∼25의 포화 및 불포화 지방산을 단독 혹은 2개 이상의 혼합물을 이용하였다.As the fatty acid used in the present invention, a saturated or unsaturated fatty acid having 6 to 25 carbon atoms was used alone or as a mixture of two or more thereof.

본 발명에 사용한 인지질은 투과개선제(Penetration enhancer) 및 유화제로서 제품의 안정성을 고려하여 수첨화 및 수산화 인지질을 이용하였다.Phospholipids used in the present invention were hydrogenated and hydroxide phospholipids in consideration of product stability as a penetration enhancer and an emulsifier.

이와 같이 조성된 혼합물은 세라마이드가 피부세포막과 다른 조성물로 혼합된 제품에 비해 부작용이 없고 피부 침투성과 보습력이 월등히 뛰어난 결과를 보였다. 또한 다른 소수성(hydrophobic) 혹은 수용성의 치료활성 성분(Therapeutic Active Ingrediens)과 상용성이 좋을 뿐만 아니라 약물 전달성이 뛰어나 피부상처 치료용 제품의 전제제(Pre-Formulation)로서도 이용이 가능하였다.The mixture thus prepared had no side effects and had excellent skin permeability and moisturizing properties compared to the product of ceramide mixed with the skin cell membrane and other compositions. In addition, it is compatible with other hydrophobic or water-soluble therapeutic active ingredients (Therapeutic Active Ingrediens) as well as excellent drug delivery, it can be used as a pre-formulation of the product for the treatment of skin wounds.

본 발명은 세라마이드와 피토스핀고신 및 그 유도체의 효능을 충분히 발휘하기 위해 피부세포막과 동일한 조성물과 구조적 성질을 갖는 피부 보호용용 조성물 및 그의 제조방법에 관한 것이다.The present invention relates to a composition for protecting the skin having the same composition and structural properties as the skin cell membrane and a method for producing the same in order to sufficiently exhibit the efficacy of ceramide, phytospinosine and derivatives thereof.

본 발명의 조성물은 각질층 세포간 주요성분인 세라마이드, 콜레스트롤, 지방산을 비롯하여 피부내피 세포막의 주성분인 레시틴, 트리글리세라이드 및 생리활성물질인 피토스핀고신 혹은 그 유도체로 구성되어 있다.The composition of the present invention is composed of the main components of the stratum corneum cells, ceramides, cholesterol, fatty acids, lecithin, triglycerides, and phytospinosine or its derivatives, which are the main components of the skin endothelial cell membrane.

각질층의 세포막을 구성하는 지질의 조성이 여러 가지 피부질환과 연관이 있는 것으로 알려지면서 손상된 피부에 세포막의 주성분인 세라마이드, 콜레스트롤, 지방산을 공급하여 세포막을 복원하는 연구가 주목되고있다. 각질층 지질인 세라마이드, 콜레스트롤, 지방산을 적절한 비율로 혼합하여 액정의 일종인 리포좀(Liposome)을 만들어 피부에 연관돤 약물전달 시스템개발에 관한 연구에 이용하고 있다.The lipid composition of the stratum corneum is known to be associated with various skin diseases, and research has been focused on restoring the cell membrane by supplying ceramides, cholesterol, and fatty acids, which are the main components of the cell membrane, to damaged skin. Ceramide, cholesterol, and fatty acids, which are stratum corneum lipids, are mixed in an appropriate ratio to form liposomes, which are a type of liquid crystal, and are used in research on drug delivery systems related to skin.

그러나 가장 중요한 성분으로 알려진 세라마이드의 소수성(Hydrophobic)과 혼합물 내에서의 결정형성이 잘되어 안정성, 사용성, 침투성이 뛰어난 제품 개발에는 많은 어려움이 있었다. 이를 해결하기 위해서 본 발명에서는 피부세포막에 존재하는 천연물질만을 이용하고 합성계면활성제 및 용제를 사용하지 않음으로써 피부친화력이 우수하고 부작용이 없는 Oil in Water(O/W)형의 액정을 띤 피부 보호 조성물을 개발하게 되었다.However, the hydrophobic (Hydrophobic) of the ceramide, which is known as the most important component, and the crystallization in the mixture have been well formed, so there were many difficulties in developing a product having excellent stability, usability and permeability. In order to solve this problem, the present invention uses only natural materials present in the skin cell membrane and does not use synthetic surfactants and solvents to protect the skin with oil-in-water (O / W) type liquid crystals having excellent skin affinity and no side effects. The composition was developed.

본 발명에 사용한 세라마이드는 스핀고신, 피토스핀고신, 스핀가닌의 아민기에 지방산을 도입한 아마이드 유도체이다.Ceramides used in the present invention are amide derivatives in which fatty acids are introduced into amine groups of spinosine, phytospinosine and spinganine.

(본 발명에 사용한 세라마이드 유도체)(Ceramide derivative used in the present invention)

1. 스핀고신유도체1.Spin high reductant

2. 스핀가닌유도체2. Spinganine Derivatives

3. 피토스핀고신유도체3. Phytospinosine derivatives

R은 탄소수가 6∼25인 포화 및 불포화 지방산으로서 불포화 지방산인 경우에는 이중결합을 1∼2개 갖고 있으며, 포화지방산인 경우에는 α 또는 β위치에 수산기(Hydroxy group)를 갖고 있다.R is a saturated and unsaturated fatty acid having 6 to 25 carbon atoms, and in the case of unsaturated fatty acid, R has 1 to 2 double bonds, and in the case of saturated fatty acids, R has a hydroxyl group at the α or β position.

상기 세라마이드 유도체는 안정된 에멀젼을 형성할 수 있도록 바람직하게는 본 발명의 조성물의 1∼10중량% 범위로 사용된다.The ceramide derivative is preferably used in the range of 1 to 10% by weight of the composition of the present invention so as to form a stable emulsion.

본 발명에 사용한 트리글리세라이드 및 레시틴은 본 발명의 조성물의 1~10중량%로 사용된다.Triglyceride and lecithin used in the present invention are used in 1 to 10% by weight of the composition of the present invention.

본 발명에 사용한 콜레스토롤은 콜레스트롤, 콜레스트롤술페이트, 콜레스트롤헤미숙시네이트로 구성되는 군에서 선택된다. 콜레스테롤의 첨가는 액정형성에 도움을 주고 형성된 액정의 안정성을 증가시킨다. 콜레스테롤 양은 조성물의 1∼10중량%까지 사용하는 것이 바람직하나, 가장 바람직하게는 세라마이드 중량비에 대하여 40∼50중량%의 범위로 사용할 때이다.Cholesterol used in the present invention is selected from the group consisting of cholesterol, cholesterol sulfate and cholesterol hemisuccinate. The addition of cholesterol helps the formation of liquid crystals and increases the stability of the liquid crystals formed. The amount of cholesterol is preferably used up to 1 to 10% by weight of the composition, most preferably when used in the range of 40 to 50% by weight relative to the ceramide weight ratio.

본 발명에 사용한 지방산은 탄소수가 6 ∼ 25의 포화 혹은 이중결합을 1∼ 2개 각조 있는 불포화지방산으로 단독 혹은 2개이상 혼합하여 사용하였다. 지방산의 사용량은 조성물의 1∼10중량%까지 사용할 수 있으나 가장 효과적인 사용량은 세라마이드 중량비에 대하여 40∼50중량% 범위로 사용할 때이다.The fatty acids used in the present invention were used alone or in combination of two or more unsaturated fatty acids having 1 to 2 carbon atoms in saturated or double bonds having 6 to 25 carbon atoms. The fatty acid may be used in an amount of 1 to 10% by weight of the composition, but the most effective amount is when used in the range of 40 to 50% by weight based on the weight of ceramide.

본 발명의 조성물의 제조에 있어서, 각질층 지질로 액정을 형성하면서 가장 효능이 뛰어난 비율은 세라마이드:콜레스테롤:지방산을 2:1:1 중량비로 사용할 때이다. 즉 이러한 비율로 조성된 화장물을 피부에 적용하였을 때 손상된 피부보호막의 복원이 가정 효과적으로 촉진될 수 있다.In the preparation of the composition of the present invention, the most effective ratio of forming liquid crystals with stratum corneum lipids is when using ceramide: cholesterol: fatty acid in a 2: 1: 1 weight ratio. That is, when applying the cosmetic composition formed in such a ratio to the skin, the restoration of the damaged skin protection film can be effectively promoted.

본발명에 사용한 피토스핀고신은 1)피토스핀고신 자체로 단독사용하거나 용해성과 유화력을 높이기 위해 유기산을 이용하여 2)유기염 형태로 사용하거나 3) 피토스핀고신의 아민기에메칠기를 도입하여 N,N,N-트리메칠피토스핀고신 형태로 사용하거나 4)Tetraacetylphytosphingosine(TAPS) 형태로 변형하여 사용할 수 있으며 조성물의 1~10중량%의 범위내에서 사용된다.The phytospinosine used in the present invention is 1) used alone as phytospinosine or 2) as an organic salt form using an organic acid to increase solubility and emulsification power, or 3) introducing a methyl group to the amine group of phytospinosine N, It can be used in the form of N, N-trimethylphytospinosine or 4) Tetraacetylphytosphingosine (TAPS). It can be used within the range of 1 to 10% by weight of the composition.

1.유기염1.organic salts

유기산을 이용하여 pH가 중성인 유기염을 만들었으며 사용한 유기산은 염화수소, 젖산을 비롯한 α- 혹은 β-히드록실산(Hydroxy Acid), 살리실산(Salicylic Acid)이다. 이들 산은 피부세포를 활성화하는 것으로 알려져 있으나 높은 산성으로 인하여 피부보호용 제품에 이용하기가 어려웠으나 피토스핀고신의 중화로 인하여 그러한 문제점이 보완되었다.Organic acids were used to make organic salts with a neutral pH. The organic acids used were α- or β-hydroxy acids, such as hydrogen chloride and lactic acid, and salicylic acid. Although these acids are known to activate skin cells, they are difficult to use in skin care products because of their high acidity.

2.양이온2.Cation

피토스핀고신의 아민기에 메칠기를 도입하여 N,N,N-트리메칠피토스핀고신(N,N,N-Trimethylphytosphingosine)을 합성하였다.N, N, N-trimethylphytosphingosine was synthesized by introducing a methyl group to the amine group of phytospinosine.

3. Tetraacetylphytosphingosine(TAPS).3. Tetraacetylphytosphingosine (TAPS).

피토스핀고신으로부터 합성하여 사용하였다.It was synthesized from phytospinosine and used.

피토스핀고신은 각질층의 세포막에 1중량% 이하로 소량 존재하나 미생물에 대하여 항생력이 있어 피부가 미생물로부터 정상적인 건강한 상태를 유지하는데 기여할 뿐만 아니라 세라마이드 형성의 전구체 역할을 하는 생리활성 물질이다. 본 발명에서 제조한 조성물에 대하여 여드름이 있는 대상자를 통한 치유 실험을 한 결과 좋은 효과를 입증할 수 있었다.Phytospinosine is present in a small amount of less than 1% by weight in the stratum corneum of the stratum corneum, but it has antimicrobial activity, which contributes to maintaining the normal healthy state of the skin from microorganisms, and is a bioactive substance that serves as a precursor of ceramide formation. Healing experiments through the subjects with acne for the composition prepared in the present invention was able to demonstrate a good effect.

레시틴은 생체막의 중요한 성분으로 지질이중막을 형성하고 물속에서 리포좀을 형성하는 성질로 인하여 약물의 전달체계 연구에 가장 많이 사용되고 있는 물질이다. 이런 용도 외에도 거친 피부를 부드럽게 해주는 유화제(Softner), 피부투과개선제(Skin Penetration Enhencer)로도 사용된다.Lecithin is an important component of biomembrane, which is the most used substance for drug delivery system research due to the formation of lipid bilayer and liposomes in water. In addition to these applications, it is also used as an emulsifier (Skinner) and Skin Penetration Enhencer to soften rough skin.

본 발명에서 사용한 레시틴은 산화안정성을 고려하여 수첨화(Hydrogenation) 혹은 수산화(Hydroxylation)된 요오드(Iodine Value)가 20 전후인 인지질을 사용하였다.In the lecithin used in the present invention, phospholipids having about 20 iodine (Iodine Value) of hydrogenation or hydroxide (Hydroxylation) were used in consideration of oxidative stability.

본 발명에 사용한 조성물은 피부에 활성이 있는 물질을 포획할 수 있는 비히클(Vehicles)을 형성하였다. 이런 성질은 치료제(Therapeutic Reagents)을 이용한 피부 보호용 제품의 전제제(Pre-Formulator)로서 사용이 가능하다.The composition used in the present invention formed vehicles (Vehicles) that can capture the active material on the skin. This property can be used as a pre-formulator for skin protection products using therapeutic agents.

(세라마이드 유도체의 제조방법)(Method for producing ceramide derivative)

1. 피토스핀고신의 유기염 제조방법1.Method of manufacturing organic salt of phytospingosin

피토스핀고신을 에탄올에 녹인 후 당량의 유기산을 가한다. 30분간 상온에서 교반후 감압하에서 에탄올을 제거한 후 아세톤을 가하여 생성된 침전물을 여과하여 건조한다(수율: 98중량%).Phytospingosin is dissolved in ethanol and an equivalent amount of organic acid is added. After stirring at room temperature for 30 minutes, the ethanol was removed under reduced pressure, and then the resultant precipitate was filtered and dried (yield: 98% by weight).

2. N,N,N,-트리메틸피토스핀고신의 제조2. Preparation of N, N, N, -trimethylphytospinosine

피토스핀고신을 클로로포름(Chloroform) 용매에 용해한 후 5당량의 소디움 카보네이트(Sodium Carbonate)와 메틸아이오다이드(Methyl Iodide)를 가하여 7시간 동안 환류 교반한다. 침전물을 여과하여 제거한 후 감압하에 용매를 제거하고 잔여물에 아세톤을 가하여 생성된 침전물을 여과하여 모아서 건조시킨 후 원하는 물질을 얻었다.(수율: 70중량%)Phytospingosin is dissolved in chloroform (Chloroform) solvent, and then 5 equivalents of sodium carbonate (Sodium Carbonate) and methyl iodide (Methyl Iodide) are added and refluxed for 7 hours. The precipitate was filtered off, the solvent was removed under reduced pressure, and acetone was added to the residue. The resulting precipitate was collected by filtration and dried to obtain the desired material. (Yield: 70% by weight)

3. TAPS3. TAPS

피토스핀고신을 무수 클로로포름에 용해한 후 5당량의 트리에틸아민(Triethylamine)을 가하고 실온으로 냉각한다.Phytospingosin is dissolved in anhydrous chloroform, and then 5 equivalents of triethylamine are added and cooled to room temperature.

아세틸언하이드라이드(Acetylanhydride) 5당량을 반응용기에 30분 동안 첨가한 후 4시간동안 환류교반한다. 실온으로 냉각 후 반응액과 동량의 물을 가하여 유기층을 분리한다. 3회 반복후 감압하에 유기용매를 날려 보내고 잔여물에 헥산(Hexane)을 가한후 재결정한다. 침전물을 여과하여 건조 후 원하는 물질을 얻었다.(수율: 95중량%).5 equivalents of Acetylanhydride is added to the reaction vessel for 30 minutes, followed by stirring under reflux for 4 hours. After cooling to room temperature, the reaction solution and the same amount of water are added to separate the organic layer. After three repetitions, the organic solvent is blown off under reduced pressure, and hexane is added to the residue, followed by recrystallization. The precipitate was filtered off to yield the desired material after drying. (Yield: 95% by weight).

[실시예 1]Example 1

본 발명의 피부 보호용 조성물은 지질상과 수상으로 나누어 제조한 뒤에 수상을 지질상에 서서히 첨가하여 제조한다. 먼저, 지질상은 트리글리세라이드 5g에 스테아린산 1.5g을 가하여 온도를 80℃까지 승온시킨다. 혼합물이 완전히 용해되면 콜레스테롤 3g. 세라마이드 5g을 가하여 용해될때까지 교반시킨다. 레시틴 2g을 가하여 용해시킨 후에 올레인산 1.5g을 가한다. 수상은 증류수 79.2g을 80℃까지 승온시킨다. 피토스핀고신 2g과 젖산 0.8g을 가하여 완전히 용해될때까지 교반시킨다. 용해된 수상을 지질상에 서서히 가하여 80℃에서 30분간 교반시킨 후 실온에서 서서히 냉각하여 크림상의 조성물을 수득하였다.The skin protection composition of the present invention is prepared by dividing the lipid phase and the aqueous phase and then slowly adding the aqueous phase to the lipid phase. First, 1.5 g of stearic acid is added to 5 g of triglycerides, and a lipid phase is heated up to 80 degreeC. When the mixture is completely dissolved, 3 g of cholesterol. Add 5 g of ceramide and stir until dissolved. After adding 2 g of lecithin to dissolve, 1.5 g of oleic acid is added. The aqueous phase raises 79.2 g of distilled water to 80 degreeC. Add 2 g of phytospingosin and 0.8 g of lactic acid and stir until complete dissolution. The dissolved aqueous phase was slowly added to the lipid phase, stirred at 80 ° C. for 30 minutes, and then cooled slowly at room temperature to obtain a creamy composition.

[실시예 2]Example 2

상기 실시예 1과 동일한 방법으로 지질상은 트리글리세라이드 5g에 스테아린산 2g을 가하여 온도를 80℃까지 승온시킨다. 혼합물이 완전히 용해되면 콜레스테롤 3g. 세라마이드 5g을 가하여 용해될때까지 교반시킨다. 수상은 증류수 82.3.g을 80℃까지 승온시킨다. 피토스핀고신 2g과 젖산 0.7g을 가하여 완전히 용해될때까지 교반시킨다. 용해된 수상을 지질상에 서서히 가하여 80℃에서 25분간 교반시킨 후 실온에서 서서히 냉각하여 크림상의 조성물을 수득하였다.In the same manner as in Example 1, 2 g of stearic acid is added to 5 g of triglyceride to raise the temperature to 80 ° C. When the mixture is completely dissolved, 3 g of cholesterol. Add 5 g of ceramide and stir until dissolved. The aqueous phase raises 82.3.g of distilled water to 80 degreeC. Add 2 g of phytospingosin and 0.7 g of lactic acid and stir until complete dissolution. The dissolved aqueous phase was slowly added to the lipid phase, stirred at 80 ° C. for 25 minutes, and then cooled slowly at room temperature to obtain a creamy composition.

[실시예 3]Example 3

지질상은 트리글리세라이드 3g에 스테아린산 1g을 가하여 온도를 80℃까지 승온시킨다. 혼합물이 완전히 용해되면 콜레스테롤 3g, TAPS 2g 및 세라마이드 5g을 가하여 용해될때까지 교반시킨다. 레시틴 2g을 가하여 용해시킨 후에 올레인산 1g 및 리놀레인산 1g을 차례로 교반하에 서서히 가한다. 수상은 증류수 80g을 80℃까지 승온시킨후에 피토스핀고신염(Phytosphingosine??Hcl) 2g을 가하여 완전히 용해될때까지 교반시킨다. 용해된 수상을 지질상에 서서히 가하여 80℃에서 30분간 교반시킨 후 실온에서 서서히 냉각하여 크림상의 조성물을 수득하였다.The lipid phase is heated to 80 ° C by adding 1 g of stearic acid to 3 g of triglycerides. When the mixture is completely dissolved, 3 g of cholesterol, 2 g of TAPS and 5 g of ceramide are added and stirred until dissolved. After adding 2 g of lecithin to dissolve, 1 g of oleic acid and 1 g of linoleic acid are added gradually under stirring. The water phase is heated to 80g of distilled water and then stirred until it is completely dissolved by adding 2g of Phytosphingosine ?? Hcl. The dissolved aqueous phase was slowly added to the lipid phase, stirred at 80 ° C. for 30 minutes, and then cooled slowly at room temperature to obtain a creamy composition.

본 발명에 따라 제조된 조성물은 사람피부에 적용할 수 있으며 특히 피부가 건조할때나 손상을 입었을때 피부로부터 수분의 이탈을 감소시키고 손상된 피부의 세포막의 복원에 도움을 주는 물질로 사용할 수 있다.The composition prepared according to the present invention can be applied to human skin, and especially when the skin is dry or damaged, it can be used as a material to reduce the escape of water from the skin and to restore the cell membrane of the damaged skin.

(시험예 1) 본 발명의 조성물(실시예1)의 여드름 치유효과 및 피부 보습효과Test Example 1 Acne healing effect and skin moisturizing effect of the composition (Example 1) of the present invention

한쪽 볼에 10개 이상의 면포(Comedone)가 발생한 15명의 남자 청년의 피부를 대상으로 실험을 하였다. 매일 적절한 시기에 상기 실시예 1에서 제조한 본 발명의 피부용 조성물을 얼굴에 아침, 점심, 취짐전에 1일 3회씩 도포한 결과 사람에 따라 6∼12주가 경과하여 여드름 부위가 깨끗해진 것을 육안으로 관찰할 수가 있었다.The skin was tested on 15 young men who had more than 10 comedones on one cheek. As a result of applying the skin composition of the present invention prepared in Example 1 to the face three times a day before breakfast, lunch, and soaking every day at an appropriate time every day, 6 to 12 weeks elapsed depending on the person, visually observing the acne area. I could do it.

3주가 지난 후 여드름부위가 어느 정도 가라앉은 다음 액체비중계를(Skin Surface Hydrometer. Skicon-200. Ibs Inc., Japan) 이용하여 전기 전도도를 측정한 결과를 나타내었다.After three weeks, the acne area subsided to some extent, and then the electrical conductivity was measured using a liquid hydrometer (Skin Surface Hydrometer. Skicon-200. Ibs Inc., Japan).

표1. 전기전도도 측정결과Table 1. Electrical conductivity measurement result

전기전도도 (μΩ1)Electrical Conductivity (μΩ 1 ) 치 료 전Before treatment 치 료 후After treatment 51.2±6.651.2 ± 6.6 200.5±9.7`200.5 ± 9.7`

또한 3주가 지난 후 증발량 측정기(Evaporimeter,Epi. Servo Med사 제품. 스웨덴) 를 사용하여 각질층을 통한 수분손실(TEWL, Trans-Epidermal Water Loss) 을 측정한 결과를 나타내었다.In addition, after 3 weeks, water loss through the stratum corneum (TEWL, Trans-Epidermal Water Loss) was measured using an evaporation meter (Evaporimeter, Epi. Servo Med. Sweden).

표2. 수분손실 측정결과Table 2. Moisture loss measurement result

수분손실(TEWL)Water loss (TEWL) 치 료 전Before treatment 치 료 후After treatment 50.5±2.550.5 ± 2.5 10.1±3.210.1 ± 3.2

상기 표에서 알 수 있듯이 본 발명의 조성물로 치유된 피부는 수분손실이 치료전에 비해 크게 개선된 것을 알 수 있다. 이는 본 발명의 조성물이 피부 각질층의 수분손실을 크게 감소시켜 피부장벽 기능을 향상시킴으로서 보습효과가 뛰어남을 입증하는 것이라 할 수 있다.As can be seen from the table, the skin cured with the composition of the present invention can be seen that the water loss is significantly improved compared to before treatment. This can be said that the composition of the present invention greatly reduces the water loss of the stratum corneum layer to improve the skin barrier function, excellent moisturizing effect.

(시험예 2) 본 발명 조성물의 상처 치유효과Test Example 2 Wound Healing Effect of the Composition of the Present Invention

2-1 조성물(실시예1)의 자상(stab)에 대한 효능실험2-1 Efficacy test on stab of composition (Example 1)

피부 절개창(pierced wound)에 대한 장력(tension strength)을 측정함으로써 상처의 유작도를 측정하여 상처치료 효능을 알아보는 것이다. 이 방법은 Schulte and Domenjoz의 방법을 일부 개량하여 실시하였다.By measuring the tension strength of the pierced wound (skin wound) by measuring the degree of injury of the wound to determine the efficacy of the wound treatment. This method was implemented with some modifications of Schulte and Domenjoz's method.

일정체중의 Sprague-Dawley계 웅성 백서(male rat)를 사용하고, 사육환경은 온도 22±2℃, 습도 50±5%의 조건에서 일주일 이상 적응시킨 후 일반적인 이상 징후가 없는 실험동물을 선별하여 사용하였다. 예비사육 및 실험기간 동안 물과 사료를 자유로이 섭취하도록 하며, 실험기간 중에는 모든 실험동물은 개별 Cage에서 사육하였다. 실험군은 표 1과 같이 나누어 각 군마다 5마리씩 실험에 임하였다. Blank군은 아무것도 투여하지 않은 군이고 , 대조군은 약국이나 병원에서 연고제 기제(Base)로 쓰이는 오인먼트 기제(Ointment base)를 투여하였다.Sprague-Dawley male rats of constant weight are used, and the breeding environment is adapted for at least one week at a temperature of 22 ± 2 ℃ and a humidity of 50 ± 5%, and then selected and used as experimental animals without general signs of abnormality. It was. During the preliminary breeding and experiment period, water and feed were freely ingested. During the experimental period, all experimental animals were raised in individual cages. The experimental groups were divided into five groups for each group as shown in Table 1. Blank group was administered nothing, and the control group was administered to the base (Ointment base) used as the ointment base (Base) in pharmacies or hospitals.

쥐 등 부위의 털을 클리퍼(Clipper)로 깎아내고, 에테르(Ether) 마취하에 70% 알코올로 피부를 소독한 후 목선에서 3 cm 떨어진 곳에서부터 정중선을 따라 등 부위 피부를 외과용 메스(Surgical knife)로 2cm 절개한 후 0.5cm 간격으로 봉합(Suture)하였다. 감염방지를 위해 항생제를 4일간 1일 1회 근육주사(i.m. = Intra-Muscular Injection)하였다. 시험물질을 수술 당일로부터 1일 1회 일정량 도포하였다. 수술 5일 후 봉합사를 제거하고, 수술 7일째 창상부를 포함하는 피부를 적출하여 장력측정기로 창상부의 장력을 측정하였다.(C.K.Kim et al. J. Kor. Pharm. Sci., vol.27. No. 2. 139-143,1997 ), (R. Schulte and R. Domenjoz. Med. Pharmacol. Exp. 16. 453-458 ,1967 )The hair on the rat's back is clipped with a clipper, the skin is disinfected with 70% alcohol under ether anesthesia, and a surgical knife is placed on the back skin along the midline from 3 cm away from the neckline. 2cm incision was made and sutured at 0.5cm intervals. To prevent infection, antibiotics were injected once daily for 4 days (i.m. = Intra-Muscular Injection). The test substance was applied once a day from the day of surgery. Five days after the operation, the suture was removed, and the skin including the wound was removed on the seventh day of surgery, and the tension of the wound was measured by a tension meter (CKKim et al. J. Kor. Pharm. Sci., Vol. 27. No. 2.139-143,1997), (R. Schulte and R. Domenjoz. Med. Pharmacol.Exp. 16. 453-458,1967)

측정된 결과는 하단 표에 나타내었다.The measured results are shown in the table below.

표에 나타낸 결과로부터 본 발명의 조성물(실시예1)의 상처 치유효과가 뚜렸하게 나타냄을 밝혀 내었고, 대조군의 상처치유 효과가 Blank군보다 높게 나타난 것은 연고기제의 기본적인 보습효과에 의한 것으로 보인다.From the results shown in the table, it was found that the wound healing effect of the composition of the present invention (Example 1) was overshadowed, and the wound healing effect of the control group was higher than that of the Blank group, which may be due to the basic moisturizing effect of the ointment.

표 3. 장력 측정결과Table 3. Tension Measurement Results

시험군 장력(중량%)Test group tension (% by weight) Blank군 100대조크림군 125본 발명(실시예1) 150Blank group 100 coarse cream group 125 invention (Example 1) 150

(시험예 3) 상처부위(Wound Area) 측정법에 의한 상처 치유효과Test Example 3 Wound Healing Effect by Wound Area Measurement Method

피부를 직경 6mm의 원형으로 절취한 부위의 복원을 측정함으로써 상처치료 효능을 알아보는 것이다. 이 방법은 와키타(Wakita)등의 방법을 일부 개량하여 실시하였다.The effect of wound healing is to be determined by measuring the restoration of the cut region of the skin in a 6mm diameter circle. This method was implemented by partially improving the method of Wakita et al.

일정체중의 Sprague-Dawley계 레트(rat)를 사용하였고, 사육환경은 온도 22±2℃, 습도 50±5%의 조건에서 일주일 이상 적응시킨 후 일반적인 이상 징후가 없는 시험동물을 선별하여 사용하였다. 예비사육 및 실험기간 동안 물과 사료를 자유로이 섭취하도록 하며, 실험기간 중에는 모든 실험동물은 개별 우리(Cage)에서 사육하였다.Sprague-Dawley rats with a constant weight were used, and the breeding environment was adapted for at least one week at a temperature of 22 ± 2 ° C and a humidity of 50 ± 5%. During the preliminary breeding and experimental period, water and feed were freely ingested. During the experimental period, all experimental animals were raised in individual cages.

쥐 등 부위의 털을 클리퍼로 깎아내고, 면도기로 제모하여 피부를 노출시켰다. 에테르 마취하에 70% 알코올로 피부를 소독한 후 목선에서 3cm 떨어진 곳에서부터 정중선을 피부를 Biopsy Punch로 직경 6mm의 원형으로 절취하여 외상을 만든다. 감염방지를 위해 항생제를 4일간 1일 1회 근육주사하였다. 시험물질을 수술 당일로부터 1일 1회 일정량 도포하였다. 상처의 크기는 실험 실시 후 4일, 7일, 10일 마다 투명한 필름을 상처 부위에 밀착하고 상처 모양을 정확히 본을 떠내어 그 면적을 측정하였다. 면적 측정 방법은 본을 딴 모양을 일정한 복사지에 복사기를 이용하여 400% 확대 복사한 후 그 무게를 측정하는 방법을 사용하였고, 치료율은 다음과 같이 계산하였다.The hair on the back of the rat was clipped with a clipper, and the hair was exposed by shaving with a razor. After ether disinfection of skin with 70% alcohol, cut the midline into 3mm diameter circle with Biopsy Punch from 3cm away from the neckline to make trauma. To prevent infection, antibiotics were injected once daily for four days. The test substance was applied once a day from the day of surgery. The size of the wound was measured every 4 days, 7 days, and 10 days after the experiment, and the transparent film was closely adhered to the wound area, and the wound shape was accurately drawn to determine the area of the wound. The area measuring method used a method of measuring the weight of the pattern after copying a 400% enlarged copy using a copy machine on a constant copy paper. The treatment rate was calculated as follows.

* 치료율(%) = [1 - (측정날짜의 area weight /1st day area weight)] * 100* Treatment rate (%) = [1-(area weight of measurement date / 1st day area weight)] * 100

실험군은 아래표와 같이 나누어 각 군마다 5마리씩 실험에 임하였다. Blank군은 아무것도 투여하지 않은 군이고, 대조군은 약국이나 병원에서 연고제 기제(Base)로 쓰이는 오인먼트 기제(Ointment base)를 투여하였다.( H. Wakita. Et al. J. Invest. Dermatol. 110: 253-258, 1998 )The experimental groups were divided into five groups for each group as shown in the table below. Blank group was administered nothing, and the control group was administered to the base (Ointment base) used as the ointment base (Base) in pharmacies or hospitals (H. Wakita. Et al. J. Invest. Dermatol. 110: 253-258, 1998)

측정된 결과는 아래 표에 나타내었다.The measured results are shown in the table below.

표에 나타낸 결과로부터 본 발명의 조성물(실시예 1)의 상처 치유효과가 더 월등함을 나타내었다.The results shown in the table showed that the wound healing effect of the composition (Example 1) of the present invention is superior.

표4. 상처부위(Wound Area) 측정법에 의한 상처 치유효과Table 4. Wound Healing Effect by Wound Area Measurement

시험군 치료율(%)4일 7일 10일Test Group Treatment Rate (%) 4 days 7 days 10 days Blank군 15.2 43.4 80.2대조크림군 16.6 52.7 92.5본 발명(실시예1) 22.5 61.0 96.2Blank group 15.2 43.4 80.2 Control cream group 16.6 52.7 92.5 Invention (Example 1) 22.5 61.0 96.2

이상과 같이 본 발명에 의해 제조된 피부 보호용 조성물은 세라마이드가 피부세포막과 다른 조성물로 혼합된 제품에 비해 부작용이 없고 피부 침투성과 보습력이 월등히 뛰어난 결과를 보였다. 이는 본 발명의 조성물이 피부 각질층의 수분손실을 크게 감소시켜 피부장벽 기능을 향상시킴으로서 보습효과가 뛰어남을 입증하는 것이라 할 수 있다. 또한 다른 소수성(hydrophobic) 혹은 수용성의 치료활성 성분(Therapeutic Active Ingrediens)과 상용성이 좋을 뿐만 아니라 약물 전달성이 뛰어나 여드름이나 피부상처 치유에도 효과가 큰 것으로 입증되었다.As described above, the composition for protecting skin according to the present invention has no side effects and has excellent skin permeability and moisturizing power compared to a product in which ceramide is mixed with skin cell membrane and other compositions. This can be said that the composition of the present invention greatly reduces the water loss of the stratum corneum layer to improve the skin barrier function, excellent moisturizing effect. In addition, its compatibility with other hydrophobic or water-soluble therapeutic active ingredients (Therapeutic Active Ingrediens), as well as excellent drug delivery has been proven to be effective in healing acne and skin wounds.

Claims (10)

피부지질 조성물로 된 피부 보호용 조성물에 있어서, 상기 조성물이 세라마이드, 콜레스트롤, 지방산, 트리글리세라이드, 레시틴 및 피토스핀고신 또는 이의 유도체로 구성되는 것을 특징으로 하는 피부 보호용 조성물.A skin protective composition comprising a skin lipid composition, wherein the composition is composed of ceramide, cholesterol, fatty acids, triglycerides, lecithin, phytospinosine or derivatives thereof. 제 1항에 있어서, 상기 세라마이드, 콜레스트롤 및 지방산은 2:1:1의 중량비로 조성물에 사용되는 것을 특징으로 하는 피부 보호용 조성물.The composition of claim 1, wherein the ceramide, cholesterol, and fatty acid are used in the composition in a weight ratio of 2: 1: 1. 제 1항에 있어서, 상기 레시틴, 피토스핀고신 및 그 유도체는 상기 조성물의 1내지 5중량%로 사용되는 것을 특징으로 하는 피부 보호용 조성물.According to claim 1, wherein the lecithin, phytospingosin and derivatives thereof is a skin protection composition, characterized in that used in 1 to 5% by weight of the composition. 제 1항에 있어서, 상기 세라마이드는 스핀고신, 스핀가닌, 피토스핀고신의 아민기에 지방산을 도입한 아마이드 유도체로 상기 조성물의 1∼10중량%로 사용되는 것을 특징으로 하는 피부보호용 조성물.The composition of claim 1, wherein the ceramide is an amide derivative in which a fatty acid is introduced into an amine group of spingosin, spinganine, and phytospingosin, and is used in an amount of 1 to 10% by weight of the composition. 제 4항에 있어서, 상기 지방산은 탄소수가 6내지 25인 포화 및 불포화 지방산인 것을 특징으로 하는 피부 보호용 조성물.The composition for protecting skin according to claim 4, wherein the fatty acid is a saturated and unsaturated fatty acid having 6 to 25 carbon atoms. 제 1항에 있어서, 상기 콜레스트롤은 콜레스트롤술포네이트 및 콜레스트롤헤 미숙시네이트로 구성되는 군으로부터 선택되는 것을 특징으로 하는 피부보호용 조성물.The composition of claim 1, wherein the cholesterol is selected from the group consisting of cholesterol and sulfestol and cholesterol. 제 1항에 있어서, 상기 콜레스트롤은 상기 조성물의 1내지 10중량%로 사용되는 것을 특징으로 하는 피부 보호용 조성물.The method of claim 1, wherein the cholesterol restoring composition for skin protection, characterized in that used in 1 to 10% by weight of the composition. 제 1항에 있어서, 상기 피토스핀고신 유도체는 단독으로 사용하거나 용해성과 유화력을 높이기 위해 유기산을 이용하여 유기염 형태로 사용하거나, 피토스핀고신의 아민기에메칠기를 도입하여 N,N,N-트리메칠피토스핀고신 형태로 사용하거나, Tetraacetylphytosphingosine(TAPS)형태로 사용되는 것을 특징으로 하는 피부 보호용 조성물.According to claim 1, The phytospinosine derivative is used alone or in the form of an organic salt using an organic acid to enhance solubility and emulsification, or by introducing a methyl group to the amine group of phytospinosine N, N, N-tree Skin protection composition, characterized in that used in the form of methyl phytospingosin, or used in the form of Tetraacetylphytosphingosine (TAPS). 제 1항에 있어서, 상기 조성물은 화상이나 상처로 손상된 피부의 치유에 사용되는 것을 특징으로 하는 피부 보호용 조성물.The composition of claim 1, wherein the composition is used to heal skin damaged by burns or wounds. 제 1항에 있어서, 상기 조성물은 여드름 치유에 사용되는 것을 특징으로 하는 피부 보호용 조성물.The composition of claim 1, wherein the composition is used for acne healing.
KR1019990026753A 1999-06-03 1999-07-03 Skin Care Composition For Improvement Of The Water-retaing Capacity Of The Skin And Restoration Of a Damaged Skin KR19990078610A (en)

Priority Applications (5)

Application Number Priority Date Filing Date Title
KR1019990026753A KR19990078610A (en) 1999-07-03 1999-07-03 Skin Care Composition For Improvement Of The Water-retaing Capacity Of The Skin And Restoration Of a Damaged Skin
CA002281430A CA2281430A1 (en) 1999-06-03 1999-09-03 Skin care compositions and their use in healing injured skin
JP11250846A JP2001039859A (en) 1999-07-03 1999-09-03 Composition for skin care, therapeutic agent for dermatosis and ointment base
FR9911061A FR2794366A1 (en) 1999-07-03 1999-09-03 Skin care composition useful for treating damaged skin comprises ceramide, cholesterol, fatty acids, triglyceride, lecithin and phytosphingosine or its derivatives
IT99MI001884 IT1314186B1 (en) 1999-07-03 1999-09-08 Skin care composition useful for treating damaged skin comprises ceramide, cholesterol, fatty acids, triglyceride, lecithin and phytosphingosine or its derivatives

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
KR1019990026753A KR19990078610A (en) 1999-07-03 1999-07-03 Skin Care Composition For Improvement Of The Water-retaing Capacity Of The Skin And Restoration Of a Damaged Skin

Publications (1)

Publication Number Publication Date
KR19990078610A true KR19990078610A (en) 1999-11-05

Family

ID=19599212

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019990026753A KR19990078610A (en) 1999-06-03 1999-07-03 Skin Care Composition For Improvement Of The Water-retaing Capacity Of The Skin And Restoration Of a Damaged Skin

Country Status (5)

Country Link
JP (1) JP2001039859A (en)
KR (1) KR19990078610A (en)
CA (1) CA2281430A1 (en)
FR (1) FR2794366A1 (en)
IT (1) IT1314186B1 (en)

Cited By (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6538032B1 (en) 2001-09-07 2003-03-25 Charmzone Co., Ltd. Phytosphingosine derivatives with antitumor activity
KR20030068698A (en) * 2002-02-16 2003-08-25 한국화장품주식회사 Whitening cosmetic composition containing nano multiple lamella sphere and method of producing the same
KR100396476B1 (en) * 1999-07-30 2003-09-02 주식회사 참 존 Cream Composition For Cosmetics
KR100423102B1 (en) * 2001-08-13 2004-03-16 주식회사 참 존 Phytosphingosine derivatives with antirumor activity
KR100429404B1 (en) * 2001-03-31 2004-04-29 엔프라니 주식회사 Cosmetic composition for lowering stimulation of the skin and enhancing moisturization of the skin
KR100452757B1 (en) * 2002-05-02 2004-10-12 앨트웰코스메틱 주식회사 Manufacturing Process of Skin-Care Containing Natural Ceramide, Phytosphingoshine, Colesterol and Lecithin
FR2853835A1 (en) * 2003-04-15 2004-10-22 Fabre Pierre Dermo Cosmetique Lipid-containing extracts from fruits low in lipids are useful for the topical treatment of dermal inflammations and protect the skin against physical or chemical damage by restoring the epidermal barrier
KR100867679B1 (en) * 2001-08-14 2008-11-10 주식회사 참 존 Natural liquid crystal composition and cosmetic composition containing it
KR100917302B1 (en) * 2001-12-10 2009-09-11 가오 가부시키가이샤 Ceramide emulsions
KR101422276B1 (en) * 2004-07-20 2014-07-22 카오카부시키가이샤 Oil-in-water emulsified composition

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2820038B1 (en) * 2001-01-29 2004-07-02 Dermaconcept Jmc DERMATOLOGICAL COMPOSITION FOR VETERINARY USE COMPRISING A SPHINGOID BASE
FR2820037B1 (en) * 2001-01-29 2005-12-09 Dermaconcept Jmc DERMATOLOGICAL COMPOSITION FOR VETERINARY USE COMPRISING A SPHINGOID BASE
KR100404072B1 (en) * 2001-03-12 2003-11-03 주식회사 두산 Therapeutic composition for broad spectrum dermal disease
KR20010044801A (en) * 2001-03-26 2001-06-05 최승철 N-acetylphytosphingosine retin amide derivatives and preparation process thereof
SE0102087D0 (en) * 2001-06-13 2001-06-13 Knut Haadem Med Haadem Invest Skin preparation
CN1827766B (en) * 2001-06-28 2010-08-25 徐荣祥 In vitro cell cultivation method
CH695085A5 (en) 2001-07-13 2005-12-15 Mibelle Ag Cosmetics Formulations for care of the skin after laser treatment and / or chemical peels, and use of formulations.
DE60117900D1 (en) * 2001-09-05 2006-05-11 Charmzone Co Phytosphingosine derivatives with anti-tumor activity
JP4806519B2 (en) * 2002-03-13 2011-11-02 トマス スコルド Water based delivery system
AU2003224486A1 (en) * 2002-05-02 2003-11-17 Doosan Corporation Composition for treating cancer containing n,n-dimethylphytosphingosine
EP1539125A4 (en) * 2002-08-14 2005-09-14 Kim Tae Yoon A composition comprising phytospingosine derivatives for apoptosis induction
CH693624A5 (en) * 2003-05-22 2003-11-28 Gecomwert Anstalt A preparation for sun protection, tanning and/or treating skin
JP3967292B2 (en) * 2003-06-10 2007-08-29 花王株式会社 Water-in-oil emulsion composition
WO2005044217A1 (en) * 2003-11-11 2005-05-19 Doosan Corporation Method for preparing phytosphingosine liposome composition
KR100969181B1 (en) 2005-06-14 2010-07-09 아사히 가세이 케미칼즈 가부시키가이샤 Body surface protecting composition
JP4954531B2 (en) * 2005-10-31 2012-06-20 一丸ファルコス株式会社 Peroxisome proliferator-responsive receptor activator
JP5465871B2 (en) * 2008-12-12 2014-04-09 花王株式会社 Acne improver
CN103445975B (en) 2012-05-30 2017-08-22 花王株式会社 Emulsification cosmetic composition
EP2829303A1 (en) * 2013-07-22 2015-01-28 Johnson & Johnson Consumer Companies Inc. Compositions comprising extract of malva neglecta and method of treating a skin condition with malva neglecta
KR101687573B1 (en) 2013-08-28 2016-12-19 주식회사 엘씨에스바이오텍 Skin lipid complex
US10406088B2 (en) 2015-01-20 2019-09-10 TetraDerm Group LLC Versatile topical drug delivery vehicle and multifactorial tissue moisturizer that provides mucosal and skin barrier restoration

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR930007433A (en) * 1991-10-19 1993-05-20 최근선 Cosmetic pigments and preparation method thereof
KR940021033A (en) * 1993-03-31 1994-10-17 임충헌 Micro Multiple Sphere Composition Containing Skin Active Cosmetic Ingredients
KR960030934A (en) * 1995-02-04 1996-09-17 문홍석 A composition for the prevention of hair loss, hair growth promotion, acne treatment and androgenic skin disease
JPH10182401A (en) * 1996-12-20 1998-07-07 Bristol Myers Squibb Co Skin protective agent
EP0879593A2 (en) * 1997-04-17 1998-11-25 Unilever Plc Anhydrous cosmetic composition with ceramides for firming skin
WO1999047110A1 (en) * 1998-03-16 1999-09-23 Unilever Plc Cosmetic method of treating skin

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR930007433A (en) * 1991-10-19 1993-05-20 최근선 Cosmetic pigments and preparation method thereof
KR940021033A (en) * 1993-03-31 1994-10-17 임충헌 Micro Multiple Sphere Composition Containing Skin Active Cosmetic Ingredients
KR960030934A (en) * 1995-02-04 1996-09-17 문홍석 A composition for the prevention of hair loss, hair growth promotion, acne treatment and androgenic skin disease
JPH10182401A (en) * 1996-12-20 1998-07-07 Bristol Myers Squibb Co Skin protective agent
EP0879593A2 (en) * 1997-04-17 1998-11-25 Unilever Plc Anhydrous cosmetic composition with ceramides for firming skin
WO1999047110A1 (en) * 1998-03-16 1999-09-23 Unilever Plc Cosmetic method of treating skin

Cited By (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100396476B1 (en) * 1999-07-30 2003-09-02 주식회사 참 존 Cream Composition For Cosmetics
KR100429404B1 (en) * 2001-03-31 2004-04-29 엔프라니 주식회사 Cosmetic composition for lowering stimulation of the skin and enhancing moisturization of the skin
KR100423102B1 (en) * 2001-08-13 2004-03-16 주식회사 참 존 Phytosphingosine derivatives with antirumor activity
KR100867679B1 (en) * 2001-08-14 2008-11-10 주식회사 참 존 Natural liquid crystal composition and cosmetic composition containing it
US6538032B1 (en) 2001-09-07 2003-03-25 Charmzone Co., Ltd. Phytosphingosine derivatives with antitumor activity
KR100917302B1 (en) * 2001-12-10 2009-09-11 가오 가부시키가이샤 Ceramide emulsions
KR20030068698A (en) * 2002-02-16 2003-08-25 한국화장품주식회사 Whitening cosmetic composition containing nano multiple lamella sphere and method of producing the same
KR100452757B1 (en) * 2002-05-02 2004-10-12 앨트웰코스메틱 주식회사 Manufacturing Process of Skin-Care Containing Natural Ceramide, Phytosphingoshine, Colesterol and Lecithin
FR2853835A1 (en) * 2003-04-15 2004-10-22 Fabre Pierre Dermo Cosmetique Lipid-containing extracts from fruits low in lipids are useful for the topical treatment of dermal inflammations and protect the skin against physical or chemical damage by restoring the epidermal barrier
WO2004091639A3 (en) * 2003-04-15 2004-11-25 Fabre Pierre Dermo Cosmetique Lipid extract from fruit of low lipid content
KR101422276B1 (en) * 2004-07-20 2014-07-22 카오카부시키가이샤 Oil-in-water emulsified composition

Also Published As

Publication number Publication date
ITMI991884A1 (en) 2001-03-08
FR2794366A1 (en) 2000-12-08
CA2281430A1 (en) 2000-12-03
JP2001039859A (en) 2001-02-13
IT1314186B1 (en) 2002-12-06
ITMI991884A0 (en) 1999-09-08

Similar Documents

Publication Publication Date Title
KR19990078610A (en) Skin Care Composition For Improvement Of The Water-retaing Capacity Of The Skin And Restoration Of a Damaged Skin
US9849079B2 (en) Medicinal skin protection composition with an active ingredient combination which improves the skin barrier
KR100371491B1 (en) Cream Composition For Skin Care
DE69927381T2 (en) MEANS FOR INCREASING SKIN LIPIDES PRODUCTION
US6964952B2 (en) Therapeutic composition for broad spectrum dermal disease
EP0863743A1 (en) Skin care preparation and method
WO2011065772A2 (en) Water in oil type cosmetic composition for improving skin
DE4021082A1 (en) Skin care product with high lipid content - contains a bi:layer source, salts of organic acids, alcohol, stabiliser and lipid(s)
EP0875232A1 (en) A lipid composition containing liquid crystal phase
JP2003508486A (en) Compositions and methods for improving skin lipid content
KR100545836B1 (en) Cosmetic composition for skin irritation relief containing nanoliposomes of intracellular lipid components
JP2001348320A (en) Lipid composition having liquid crystal structure
US6372236B1 (en) Cream composition for skin care
KR100343885B1 (en) A Process For Preparing Phytosphingosine Aqueous Solution
KR101598210B1 (en) transparent gel solubilization composition containing ceramide, peptide, and hyaluronic acid
KR102503769B1 (en) Novel sphingolipid which contains branched fatty acid and uses thereof
KR102215013B1 (en) Spherulitic structure composition comprising phytosphingosine and fatty acid and manufacturing method thereof
KR102015890B1 (en) Polysaccharide liquid crystal composition and manufacturing method thereof and cosmetic composition comprising the same
KR100824958B1 (en) Cosmetic composition containing oriental herb extract and nano ceramide
CA2432405C (en) Water-free skin care formulations comprising micronized urea and method of manufacturing the same
JP2022092861A (en) Ceramide-containing liposome
EP1216021A1 (en) Pharmaceutical and/or cosmetical compositions
DE102022108329A1 (en) Composition for treating the skin

Legal Events

Date Code Title Description
A201 Request for examination
E902 Notification of reason for refusal
E601 Decision to refuse application